New insights into the functions of inflammasomes
For diseases mediated by NLRP3, AIM2, NLRC4, and Pyrin, understanding inflammasome biology could identify therapeutic targets.
List view / Grid view
For diseases mediated by NLRP3, AIM2, NLRC4, and Pyrin, understanding inflammasome biology could identify therapeutic targets.
Using tumour organoids, researchers have found a starting point for the development of a more refined PDAC drug.
One gene involved in the production of iron-sulphur clusters may be crucial for the persistence of Mycobacterium tuberculosis.
Researchers developed a personalised stem cell therapy using a data-driven, single-cell technique based on swift subcellular proteomic imaging.
Biomarkers found through urinary and exosome proteome profiling have potential for diagnosis and disease monitoring.
Founder and CSO of Achilles Therapeutics Dr Sergio Quezada reveals how the landmark TRACERx study has gleaned key insights that could make the difference between success and failure in immunotherapy treatment.
Cofounder & Chief Scientific Officer of Pheast Therapeutics, Dr Roy Maute, reveals his company’s promising drug candidate and explains why they have focused on their chosen target.
The new antibodies can neutralise certain H1 and H3 strains with or without the 133a insertion, which could lead to improved vaccines.
Using shRNA screening enabled researchers to investigate the roles of individual specific factors in maintaining the network found in AML.
From a database of more than 200,000 high-resolution, three-dimensional images of human induced pluripotent stem cells, researchers have devised a model to quantify cell shape and internal organisation. Susanne Rafelski, Deputy Director of the Allen Institute for Cell Science, revealed details of their study to Drug Target Review.
21 December 2023 | By
A new Drug Target Review issue is now ready to download! This issue features articles on CRISPR, personalised medicine and screening.
In the rapidly evolving landscape of mRNA biology and artificial intelligence (AI), Anima Biotech stands at the forefront, a unique approach that reshapes our understanding of diseases and transforms the drug discovery process. mRNA biology holds immense potential with RNAi drugs in the market and mRNA vaccines showing promise, particularly…
A new finding that pathological alpha-synuclein causes cells to increase protein synthesis suggests new targets for treating PD.
The first multi-chamber cardioids derived from hiPSCs have enabled scientists to investigate heart development and defects.
New understanding of the communication system between pathogens and host cells provides a way to avoid antimicrobial resistance.